Abu Dhabi: Abu Dhabi Health Data Services (ADHDS), part of M42’s Digital Health Solutions (DHS) platform, has announced a collaboration with Syndesis Health, a major holder of phenotype data, encompassing over 70 million patient profiles.
According to Emirates News Agency, the term sheet was signed by Kareem Shahin, CEO of M42’s Digital Health Solutions platform, and Josh Sutton, CEO of Syndesis Health. This collaboration reinforces Abu Dhabi’s position as a global hub for digital health innovation.
This partnership merges Syndesis Health’s extensive phenotype database with ADHDS’s digital health infrastructure to advance AI-powered genomic analytics, precision medicine, and drug discovery. By integrating real-world data with advanced artificial intelligence, the collaboration aims to accelerate innovation in clinical decision support and pharmaceutical research, ultimately improving treatment pathways for patients worldwide.
The collaboration will focus on three key areas: commercializing phenotype data to support global pharmaceutical, biotech, and academic research; developing AI-driven predictive models that enable personalized, data-driven healthcare while maintaining compliance with international data governance standards; and enhancing genomic analytics to improve prescription safety and reduce adverse drug reactions through AI-powered pharmacogenomics.
The parties have signed a term sheet outlining their intent to establish a joint venture focused on generating valuable insights to accelerate drug development, enhance patient outcomes, and support the advancement of healthcare infrastructure. This potential collaboration aligns with Abu Dhabi’s vision of positioning itself as a global leader in digital health and biomedical research.
Kareem Shahin, CEO of M42’s Digital Health Solutions platform, emphasized the significance of the partnership, stating, “This collaboration represents a major step forward in harnessing real-world data and AI to transform healthcare. By integrating Syndesis Health’s vast phenotype dataset with our digital health expertise, we are opening new frontiers in genomic analytics and drug discovery.”
Josh Sutton, CEO of Syndesis Health, added, “The collaboration between Syndesis Health and ADHDS will generate groundbreaking insights that accelerate pharmaceutical innovation and improve patient outcomes. Together, we are setting new benchmarks for AI-driven healthcare solutions.”
With a shared commitment to advancing global healthcare through data-driven innovation, this partnership marks a significant milestone in the evolution of precision medicine and AI-powered drug discovery.